Atlas Trials

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Clinical trial NCT02953678 · COMPLETED

Trial details

NCT number
NCT02953678
Sponsor
Incyte Corporation
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Graft-versus-host Disease (GVHD)
Start date
2016-12-30
Primary completion
2018-01-31
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.